{"id":53501,"date":"2023-02-01T08:02:15","date_gmt":"2023-02-01T07:02:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/"},"modified":"2023-02-01T08:02:15","modified_gmt":"2023-02-01T07:02:15","slug":"shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/","title":{"rendered":"Shin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor"},"content":{"rendered":"
\n

\n– Former Chief Cabinet Secretary Yasuhisa Shiozaki appointed as special advisor\n<\/p>\n

<\/a><\/p>\n

TOKYO–(BUSINESS WIRE)–Shin-Nihon Public Affairs Co. (Head Office: Tokyo; President: Yasushi Kohara) today announced Mr. Yasuhisa Shiozaki as special advisor. Mr. Shiozaki is a former Chief Cabinet Secretary, and Minister of Health, Labour and Welfare, and is well versed in an extremely wide range of policy areas.\n<\/p>\n

\n\u201cI will utilize my knowledge and experience I have accumulated over many years in the fields of politics and public administration to develop a variety of policy advocacy activities aimed at solving global issues,” said Shiozaki upon the appointment.\n<\/p>\n

\nWhen he served as Minister of Health, Labour, and Welfare, he led to launch the Action Plan for Whole Genome Analysis, etc. to promote genomic medicine for cancer and intractable diseases, and strongly promoted data health reform. He also worked on many other policy issues, including the issue of drug resistance (AMR). After becoming a private citizen, he established the Study Group for the Promotion of Genomic Medicine in February 2022, which he continues to preside over and disseminate policy proposals for the realization of “patient-driven, patient-rewarded” genomic medicine.\n<\/p>\n

\n\u201cMr. Shiozaki\u2019s extensive experience in government and public administration will serve us well as we continue to provide a higher level of policy advocacy services, especially in the medical field to support the fostering of the genome industry as well as the raising of the overall healthcare industry toward the goal of becoming a \u201cHealth Advanced Nation\u201d,\u201d said Kohara.\n<\/p>\n

\nRead Shiozaki\u2019s full biography at https:\/\/www.y-shiozaki.or.jp\/en\/profile\/index.html<\/a>
Learn more at https:\/\/www.snpa.co.jp\/en\/<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nYasushi Kohara
\n
+81-50-6882-8582
\n
contact_us@snpa.co.jp<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Former Chief Cabinet Secretary Yasuhisa Shiozaki appointed as special advisor TOKYO–(BUSINESS WIRE)–Shin-Nihon Public Affairs Co. (Head Office: Tokyo; President: Yasushi Kohara) today announced Mr. Yasuhisa Shiozaki as special advisor. Mr. Shiozaki is a former Chief Cabinet Secretary, and Minister of Health, Labour and Welfare, and is well versed in an extremely wide range of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53501","6":"format-standard","7":"category-industry"},"yoast_head":"\nShin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Former Chief Cabinet Secretary Yasuhisa Shiozaki appointed as special advisor TOKYO–(BUSINESS WIRE)–Shin-Nihon Public Affairs Co. (Head Office: Tokyo; President: Yasushi Kohara) today announced Mr. Yasuhisa Shiozaki as special advisor. Mr. Shiozaki is a former Chief Cabinet Secretary, and Minister of Health, Labour and Welfare, and is well versed in an extremely wide range of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T07:02:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230130005801\/en\/1702215\/21\/53294278_SHIN-NIHON_PUBLIC_AFFAIRS_230131171109_profile_2021_%28002%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Shin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor\",\"datePublished\":\"2023-02-01T07:02:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\\\/\"},\"wordCount\":292,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005801\\\/en\\\/1702215\\\/21\\\/53294278_SHIN-NIHON_PUBLIC_AFFAIRS_230131171109_profile_2021_%28002%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\\\/\",\"name\":\"Shin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005801\\\/en\\\/1702215\\\/21\\\/53294278_SHIN-NIHON_PUBLIC_AFFAIRS_230131171109_profile_2021_%28002%29.jpg\",\"datePublished\":\"2023-02-01T07:02:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005801\\\/en\\\/1702215\\\/21\\\/53294278_SHIN-NIHON_PUBLIC_AFFAIRS_230131171109_profile_2021_%28002%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005801\\\/en\\\/1702215\\\/21\\\/53294278_SHIN-NIHON_PUBLIC_AFFAIRS_230131171109_profile_2021_%28002%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/","og_locale":"en_US","og_type":"article","og_title":"Shin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor - Pharma Trend","og_description":"– Former Chief Cabinet Secretary Yasuhisa Shiozaki appointed as special advisor TOKYO–(BUSINESS WIRE)–Shin-Nihon Public Affairs Co. (Head Office: Tokyo; President: Yasushi Kohara) today announced Mr. Yasuhisa Shiozaki as special advisor. Mr. Shiozaki is a former Chief Cabinet Secretary, and Minister of Health, Labour and Welfare, and is well versed in an extremely wide range of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-01T07:02:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230130005801\/en\/1702215\/21\/53294278_SHIN-NIHON_PUBLIC_AFFAIRS_230131171109_profile_2021_%28002%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Shin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor","datePublished":"2023-02-01T07:02:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/"},"wordCount":292,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230130005801\/en\/1702215\/21\/53294278_SHIN-NIHON_PUBLIC_AFFAIRS_230131171109_profile_2021_%28002%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/","url":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/","name":"Shin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230130005801\/en\/1702215\/21\/53294278_SHIN-NIHON_PUBLIC_AFFAIRS_230131171109_profile_2021_%28002%29.jpg","datePublished":"2023-02-01T07:02:15+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230130005801\/en\/1702215\/21\/53294278_SHIN-NIHON_PUBLIC_AFFAIRS_230131171109_profile_2021_%28002%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230130005801\/en\/1702215\/21\/53294278_SHIN-NIHON_PUBLIC_AFFAIRS_230131171109_profile_2021_%28002%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/shin-nihon-public-affairs-announces-yasuhisa-shiozaki-to-join-as-special-advisor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Shin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53501"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53501\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}